On April 5, 2024, Julie VanOrsdel Daves MSHS, CCRP notified her resignation as Senior Vice President, Clinical Development Operations of DiaMedica Therapeutics Inc. ("DiaMedica"), effective as of April 18, 2024, for personal reasons. Following the departure of Ms. Daves, Rebekah de Vitry Fries, who currently serves as DiaMedica's Vice President of Clinical Operations, will assume leadership of DiaMedica's clinical operations. Rebekah joined DiaMedica as a consultant on January 3, 2024 and a full-time employee on February 20, 2024, and brings extensive experience and knowledge in clinical operations, having previously served as the Head of Clinical Operations at Epygenix Therapeutics Inc. where she also reported directly to Lorianne Musuoka, M.D., DiaMedica's Chief Medical Officer.

DiaMedica believes that the experience and leadership of Ms. De Vitry Fries will ensure a smooth transition and continued excellence in its clinical development operations.